top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Share : Technological Growth Map with an Impact-Analysis

0 votes
6 views

The global helicobacter pylori (H. pylori) non-invasive testing market was valued at approximately US$ 518.0 Mn in 2017 and is projected to register a compounded annual growth rate (CAGR) of over 3.99% from 2018 to 2026, according to a new report titled, “Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”, published by Transparency Market Research (TMR).

The report suggests that factors, such as, rise in the adoption of non-invasive testing for diagnosis of H. pylori, lack of endoscopic facilities, and upcoming technologically-advanced tests from global market players for non-invasive helicobacter pylori testing in the next few years (2018-2026) are likely to boost the demand for global helicobacter pylori (H. pylori) non-invasive tests. High awareness and diagnosis rate of H. pylori infection in North America and high prevalence of the disease in East-European countries are likely to generate a significant share for the market in North America and Europe from 2018 to 2026.

Get a Glimpse of the In-Depth Analysis through our Comprehensive “Helicobacter Pylori (H. Pylori) Non-invasive Testing Market” Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45312

Rise in adoption of non-invasive tests for H. pylori diagnosis globally to fuel the market

There has been a growing preference for non-invasive tests globally for H. pylori infection testing among patients as well as health care providers, owing to quick turnaround time for test results, higher patient compliance, and reduced discomfort usually associated with invasive tests. At the same time, these tests are high in accuracy and specificity to aid the correct diagnosis of the H. pylori infection. Non-invasive tests are also cost-effective compared to invasive endoscopic options.

Serology test segment to lose market share

Among non-invasive tests, serology test is commonly prescribed by health care practitioners for H. pylori owing to the relatively lower cost and ease of conducting of the test. However, the serology test segment is expected to lose its market share during the forecast period. Regional agencies such as American Gastroenterology Association (AGA) and National Health Services (NHS) have updated their guidelines to prevent the use of serology testing for detection of H. pylori due to high incidence rate of false positives, lower specificity as compared to other non-invasive testing methods, and inability to test for eradication of the H. pylori infection in a patient associated with the test. The serology test segment is estimated to hold a market share of 30.3% by the end of 2018, while its market share is anticipated to drop to 13.7% by the end of 2026.

Laboratory-based tests segment to witness significant growth

Among test methods, the laboratory-based tests segment of the global helicobacter pylori (h. pylori) non-invasive testing market is estimated to witness a significant growth during the forecast period. The segment is likely to expand at a CAGR of 3.73% between 2018 and 2026. Growth of the segment can be ascribed to the fact that a majority of these tests are performed in laboratory settings, based on laboratory methods, conducted by trained professionals in a controlled environment. Laboratories are capable of conducting high volume of tests per day and providing the results in a few hours or a few days (1 to 2 days). According to WHO, in Asia Pacific, an estimated 70% of health decisions are based on laboratory results, as laboratory-based tests provide essential support and facilitate appropriate medical intervention.

Diagnostic laboratories to be highly promising among end-users

Among end users, the diagnostic laboratories segment is expected to hold the leading i.e. 47.5% share of the market by 2026. This can be attributed to the large number of H. pylori non-invasive tests performed by standalone and hospital-based diagnostic laboratories. Moreover, presence of major standalone laboratories, testing a large number of patient, and high adoption of new tests and instruments by diagnostic laboratories for diagnosis of H. pylori, is expected to fuel the growth of the diagnostic laboratories segment through 2026.

Asia Pacific to witness significant growth and create high incremental opportunity

The helicobacter pylori (H. pylori) non-invasive testing market in Asia Pacific is estimated to expand at a significant CAGR of 4.52% during the forecast period. The market in the region is likely to be driven by the high prevalence of H. pylori in rural India, (80% or even more), where a vast population is living under poverty and gastric cancer burden, linked to H. pylori bacteria, is relatively high. North America is expected to hold the leading market share of 31.1% by 2026, due to rising incidence of gastric adenocarcinoma, peptic ulcers, and other diseases which are strongly associated with H. pylori infection. This has prompted national and regional health care agencies in the U.S. to actively promote non-invasive diagnostic tests for chronic as well as acute dyspeptic patients, with an aim to eradicate H. pylori infection from among the prevalent population. The helicobacter pylori (H. pylori) non-invasive testing market in North America is likely to register a CAGR of 3.62% during the forecast period.

Key players to continue leading global helicobacter pylori (H. pylori) non-invasive testing market

Prominent players operating in the global helicobacter pylori (h. pylori) non-invasive testing market are DiaSorin S.p.A., Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Alere, Thermo Fisher Scientific, Biomerica, Inc., Certest Biotec S.L., Sekisui Diagnostics, CorisBioconcept SPRL and Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd. These key players are expected to maintain their key positions during the forecast period.

More Trending Reports by Transparency Market Research –

Hearing Aids Market: prnewswire.com/news-releases/hearing-aids-market-increasing-prevalence-of-hearing-loss-worldwide-augments-product-demand-says-tmr-300857268.html

Global Wound Healing Market: prnewswire.com/news-releases/global-wound-healing-market-to-reach-over-us-350-billion-by-2025-says-tmr-676809663.html

posted Feb 12 by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

The global helicobacter pylori (H. pylori) non-invasive testing market was valued at approximately US$ 518.0 Mn in 2017 and is projected to register a compounded annual growth rate (CAGR) of over 3.99% from 2018 to 2026, according to a new report titled, “Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”, published by Transparency Market Research (TMR). 

The report suggests that factors, such as, rise in the adoption of non-invasive testing for diagnosis of H. pylori, lack of endoscopic facilities, and upcoming technologically-advanced tests from global market players for non-invasive helicobacter pylori testing in the next few years (2018-2026) are likely to boost the demand for global helicobacter pylori (H. pylori) non-invasive tests. High awareness and diagnosis rate of H. pylori infection in North America and high prevalence of the disease in East-European countries are likely to generate a significant share for the market in North America and Europe from 2018 to 2026.

Rise in adoption of non-invasive tests for H. pylori diagnosis globally to fuel the market

There has been a growing preference for non-invasive tests globally for H. pylori infection testing among patients as well as health care providers, owing to quick turnaround time for test results, higher patient compliance, and reduced discomfort usually associated with invasive tests. At the same time, these tests are high in accuracy and specificity to aid the correct diagnosis of the H. pylori infection. Non-invasive tests are also cost-effective compared to invasive endoscopic options.

Request PDF Sample of Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=45312

Serology test segment to lose market share

Among non-invasive tests, serology test is commonly prescribed by health care practitioners for H. pylori owing to the relatively lower cost and ease of conducting of the test. However, the serology test segment is expected to lose its market share during the forecast period. Regional agencies such as American Gastroenterology Association (AGA) and National Health Services (NHS) have updated their guidelines to prevent the use of serology testing for detection of H. pylori due to high incidence rate of false positives, lower specificity as compared to other non-invasive testing methods, and inability to test for eradication of the H. pylori infection in a patient associated with the test. The serology test segment is estimated to hold a market share of 30.3% by the end of 2018, while its market share is anticipated to drop to 13.7% by the end of 2026.

Laboratory-based tests segment to witness significant growth

Among test methods, the laboratory-based tests segment of the global helicobacter pylori (h. pylori) non-invasive testing market is estimated to witness a significant growth during the forecast period. The segment is likely to expand at a CAGR of 3.73% between 2018 and 2026. Growth of the segment can be ascribed to the fact that a majority of these tests are performed in laboratory settings, based on laboratory methods, conducted by trained professionals in a controlled environment. Laboratories are capable of conducting high volume of tests per day and providing the results in a few hours or a few days (1 to 2 days). According to WHO, in Asia Pacific, an estimated 70% of health decisions are based on laboratory results, as laboratory-based tests provide essential support and facilitate appropriate medical intervention.

Diagnostic laboratories to be highly promising among end-users

Among end users, the diagnostic laboratories segment is expected to hold the leading i.e. 47.5% share of the market by 2026. This can be attributed to the large number of H. pylori non-invasive tests performed by standalone and hospital-based diagnostic laboratories. Moreover, presence of major standalone laboratories, testing a large number of patient, and high adoption of new tests and instruments by diagnostic laboratories for diagnosis of H. pylori, is expected to fuel the growth of the diagnostic laboratories segment through 2026.

Buy Now “Helicobacter Pylori (H. Pylori) Non-invasive Testing Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=45312&ltype=S

Asia Pacific to witness significant growth and create high incremental opportunity

The helicobacter pylori (H. pylori) non-invasive testing market in Asia Pacific is estimated to expand at a significant CAGR of 4.52% during the forecast period. The market in the region is likely to be driven by the high prevalence of H. pylori in rural India, (80% or even more), where a vast population is living under poverty and gastric cancer burden, linked to H. pylori bacteria, is relatively high. North America is expected to hold the leading market share of 31.1% by 2026, due to rising incidence of gastric adenocarcinoma, peptic ulcers, and other diseases which are strongly associated with H. pylori infection.

This has prompted national and regional health care agencies in the U.S. to actively promote non-invasive diagnostic tests for chronic as well as acute dyspeptic patients, with an aim to eradicate H. pylori infection from among the prevalent population. The helicobacter pylori (H. pylori) non-invasive testing market in North America is likely to register a CAGR of 3.62% during the forecast period.

Key players to continue leading global helicobacter pylori (H. pylori) non-invasive testing market

Prominent players operating in the global helicobacter pylori (h. pylori) non-invasive testing market are DiaSorin S.p.A., Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Alere, Thermo Fisher Scientific, Biomerica, Inc., Certest Biotec S.L., Sekisui Diagnostics, CorisBioconcept SPRL and Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd. These key players are expected to maintain their key positions during the forecast period.

More Trending Reports by Transparency Market Research –

Personal Mobility Devices Market: prnewswire.com/news-releases/personal-mobility-devices-market-to-touch-us-146-bn-by-2024-propelled-by-rising-preference-for-electric-wheelchairs-a-new-report-by-tmr-589847341.html

Global Wound Healing Market: prnewswire.com/news-releases/global-wound-healing-market-to-reach-over-us-350-billion-by-2025-says-tmr-676809663.html

0 votes

Transparency Market Research (TMR) has published a research study on the global renal denervation devices market, expecting it to rise at an exponential CAGR of 41.20% during the period from 2012 to 2021 and reach a value of US$1.9 bn by the end of the forecast period.The market report, titled “Renal Denervation Devices Market – Global Industry Analysis, Size, Share, Growth, and Forecast 2012 – 2021,” further states that the worldwide market for renal denervation devices stood at US$88.5 mn in 2012.

Renal denervation is a relatively new therapy for the treatment of uncontrolled hypertension. It is a minimally invasive procedure and reduces the blood pressure by ablating renal nerves. Hypertension is regarded as a modifiable health risk and is often associated with morbidity and mortality due to its association with cardiovascular diseases. The development of catheter-based interventional therapies to interrupt renal sympathetic nervous system has shown impressive results in ensuring better blood pressure control in patients complaining of resistant hypertension. This, coupled with the increasing prevalence of uncontrolled as well as drug-resistant hypertension, is stimulating the demand for renal denervation procedures in the global arena.

The report has analyzed the global renal denervation devices market on the basis of products, technology, and its regional spread. Symplicity, OneShot, EnligHTN, V2, TIVUS, Paradise, Bullfrog, and Surround Sound have been identified as the main products available in this market.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=400

Based on technology, this market has been classified into radiofrequency renal denervation devices, micro-infusion renal denervation devices, and ultrasound renal denervation devices.The research report regionally segments the global market for renal denervation devices into Asia Pacific, North America, and the Rest of the World. As per the market study, Europe is the leading regional renal denervation devices market.

In 2012, Europe held a share of 80% in the global renal denervation devices market. Analysts project the region to retain its dominance over the forecast period. The rising research activities in Europe for the further development of renal denervation procedures is fueling the demand from the market in this region.

The Asia Pacific renal denervation devices market has occupied the second position in the global market and is likely to retain its position during the forecast period. The rising geriatric population in Asia Pacific, coupled with a large patient pool suffering from diabetes, is driving the demand for renal denervation devices market in this region, states the market report.

The report also expects the markets for renal denervation devices in North America and the Rest of the world to show healthy growth. The increasing approvals of these devices from the U.S. FDA are driving the North America renal denervation devices market, whereas the Rest of the World market is led by the rising incidence of lifestyle-related cardiovascular disorders, notes the study.

Some of the key manufacturers of renal denervation devices mentioned in this research study are Medtronic Inc., St. Jude Medical, Kona Medical, Boston Scientific Corp., Mercator Medsystems, Covidien Plc., and CardioSonic.

More Trending Reports by Transparency Market Research –

Insulin Pen Needles Market: prnewswire.com/news-releases/insulin-pen-needles-market-to-expand-at-a-cagr-of-8-0-till-2026-rising-need-for-therapeutic-gadgets-to-augment-global-industry—tmr-300855783.html

Bioremediation Technology & Services Market: prnewswire.com/news-releases/bioremediation-technology—services-market-to-reach-us657-bn-by-2025-globally-transparency-market-research-668429603.html

0 votes

Cardiac Holter monitors are utilized for the purpose of recording electrical activities of the heart. The device is operational on small batteries so as to record rhythm of heart for 24 to 48 hours. The holter monitor device comprises a recorder and software. The recorder is used for the purpose of recording the heart’s rhythm and the software is utilized for the purpose of interpretation of the recorded data. The cardiac holter monitor is most used for the purpose of diagnosis and analysis of bradycardia, atrial, fibrillation, and cardiac arrhythmia. Increase in government funding so as to create awareness about various cardiovascular disorders and its prevention, investments in research and development of advanced diagnostic devices, and shift of population towards preventive healthcare are the significant drivers of the said market.

A few of the important market players that are operating in the world market for cardiac holter monitor are The ScottCare Corporation, GE Healthcare, Spacelabs Healthcare, FUKUDA DENSHI, Nasiff Associates, Inc., Koninklijke Philips N.V., Biomedical Instruments Co., Ltd., Schiller, BTL, LifeWatch AG, and Welch Allyn.

Request Sample of Cardiac Holter Monitor Market Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16346

In accordance with TMR, the international market for cardiac holter monitor was to be worth around US$ 293.8 mn in the year 2015 and is expected to attain a market valuation of around US$ 518.9 mn by the end of 2024, thereby expanding at a growth rate of around 6.6% CAGR from the year 2016 to the year 2024.

Regionally, the world market for cardiac holter monitor market is divided into the Middle East and Africa, Latin America, Europe, North America, and Asia Pacific. North America holds lion’s share of the world market for cardiac holter in the year 2015, owing to increasing preference of patients towards minimally invasive diagnostic tools and better funding from government for the treatment of cardiovascular disorder.

North America is anticipated to continue with its dominance in the market for cardiac holter monitor, which is attributed to the investments that is being made by the significant market players in the industry of medical devices, and constant rise in incidences of cardiovascular disorders in the region of North America. The region of Asia Pacific is expected to be a rapidly growing segment, with a very high CAGR in the years to come.

Request for a Discount on Cardiac Holter Monitor Market Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=16346

Rising Prevalence of Cardiac Diseases to Propel the Market

Change in the diet of people that is marked with the consumption of various unhealthy food items, excessive alcohol intake, and smoking have mostly impacted the evolution of diseases and susceptibility to those diseases. Sedentary lifestyle choices like absence of exercise in their daily life have also added to the faltering condition of health of numerous people, particularly pertaining to the disorder and diseases of the heart.

As such, the increasing prevalence of cardiovascular diseases has bolstered major demand for cardiac holter monitor and it is an ambulatory ECG monitoring device that is used for the purpose of recording the electrical activities of human heart. In addition to that, the rising number of cardiac patients together with rising technological advancements is forecasted to fuel the said market.

More Trending Reports by Transparency Market Research –

Pulmonary Arterial Hypertension Market: globenewswire.com/news-release/2018/07/24/1541108/0/en/Pulmonary-Arterial-Hypertension-Market-to-reach-a-valuation-of-US-5-19-Bn-by-2020-Says-TMR.html

Autoimmune Disease Diagnostics Market: globenewswire.com/news-release/2018/12/07/1663722/0/en/Autoimmune-Disease-Diagnostics-Market-is-likely-to-reach-US-17-06-billion-by-2023-TMR.html

0 votes

The global spinal muscular atrophy market witnesses substantial competition with the presence of a considerable number of market participants of varying sizes, says Transparency Market Research (TMR) in a new market study. Savvy players are engaged in developing novel drug formulations, the success rate of which impacts market share, and trust of these companies among consumers.

For such initiatives, large players are partnering with regional companies to leverage the technological and research capabilities of the latter. The partnering of Cytokinetics Inc. with a Japanese company to develop a novel drug for spinal muscular atrophy is a case in point.

Apart from this, players in the spinal muscular atrophy market work closely with medical professionals to stay updated for therapeutic requirements from the medical consultant’s point of view. This helps keen players garner larger share in the spinal muscular atrophy market.

Request PDF Sample of Spinal Muscular Atrophy Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7187

Some key companies operating in the global spinal muscular atrophy market include AveXis Inc., Ionis Pharmaceuticals Inc., Cytokinetics Inc., F. Hoffmann-La Roche AG, and Novartis AG.

In terms of geography, North America holds prominence in the global spinal muscular atrophy market. The demand in the region stems from vast clinical research for spinal disorders in the U.S. In the U.S. and in parts of Europe, clinical research for pipeline drugs for spinal muscular atrophy receive tax rebates, thereby boosting the spinal muscular atrophy market in North America and Europe.

Onus of Governments to provide Therapeutics for Rare Diseases boosts Growth

Worldwide, governments take the onus to provide the highest standard of healthcare to the population. Governments, especially in developed countries that have substantial funds, make efforts for clinical research for therapeutics of rare diseases. The successful outcomes of such initiatives become patent, and are then sold to pharmaceutical companies and medical device manufacturers to improve therapeutics. Such initiatives for therapeutics of spinal muscular disorders is providing tailwinds to the global spinal muscular atrophy market.

Buy Now “Spinal Muscular Atrophy Market ” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=7187&ltype=S

In pharmaceutical research, drugs for spinal muscular atrophy is a key focus area. Spinal muscular atrophy disorder lacks availability of treatment, with the presence of only a handful of advanced drugs. There lies huge gap in the availability of treatment for spinal muscular atrophy to fulfill the demand.

As stated in a journal by CureSMA, almost one in fifty people carry the faulty spinal muscular atrophy gene. Such estimations are provided based on a sample population, hence, the total number of individuals carrying spinal muscular atrophy genes can be much higher. This serves to provide immense opportunities for companies in the spinal muscular atrophy market.

Stringent Regulations to receive certification for Commercialization hinders Growth

Owing to several factors such as favorable regulations, competitive intensity, drug pricing, and population, developed countries are coming up as key centers for spinal muscular atrophy research. However, stringent regulations for the commercialization of treatment of rare diseases is holding back the growth of spinal muscular atrophy market to some extent.

Nevertheless, such restraints are not likely to prevent the market from prospering. In the U.S. and in parts of Europe, governments have already identified spinal muscular atrophy as an orphan drug. As such, government funds for this category are likely to increase accordingly.

0 votes

Mesh-like tube of thin wire without coating is termed as bare-metal stent. Bare-metal stents (BMSs) made up of materials such as stainless steel, cobalt-chromium alloy, and platinum chromium alloy are used to overcome dissection and restenosis complications caused by recoil. Increase in incedence cases of coronary artery diseases and subsequent rise in the number of PCI procedures, surge in the development of bioresorbable stents, and technological advancement fuel the growth of the global bare-metal stents market.

In May 2014, Biosensors International Group, Ltd. launched next generation cobalt chromium bare-metal stent that offers exceptional deliverability, while retaining excellent radial strength and extremely low recoil. However, stringent regulatory approval process and post-operative complications are projected to hamper the growth of the global market.

Global Bare-metal Stents Market: Dynamics

Rise in Cases of Coronary Heart Diseases Boosts Market Growth

Coronary heart disease, among all other heart-related disorders, is one of the major causes of death in the U.S. Arteries that supply blood to heart become narrowed or hardened due to higher level of cholesterol or deposition of other materials called plaque in the inner wall in coronary heart disease. Coronary artery disease also weakens the heart muscles leading to heart failure and arrhythmias. According to the American Heart Association, nearly 836,546 deaths were caused in the U.S. in 2018, which is about 1 in every 3 deaths, due to cardiovascular diseases.

To Know the Scope of Our Report Get a Brochure on “Bare-metal Stents Market” here @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=72336

According to American Heart Association report, coronary heart disease accounted for 43.8% deaths among all other cardiovascular diseases in the U.S. in 2018, followed by stroke, heart failure, high blood pressure, artery related diseases, and other cardiovascular diseases. Percutaneous coronary intervention (PCI) or coronary angioplasty/stenting is one of the surgical methods to treat coronary heart disorders. Unlike invasive procedures such as coronary artery bypass surgery (CABS), stenting is a minimally invasive technique and is being widely accepted by surgeons as well as patients.

Hence, rise in prevalence of cardiovascular diseases and increase in awareness about stenting procedures across the globe are projected to drive the global bare-metal stents market during the forecast period.

Post-Operative Complications Hamper Market Growth

Percutaneous coronary intervention (PCI) with stenting is a well-accepted procedure for the treatment of cardiovascular diseases. However, 15% to 30% of patients undergoing this surgery requires repeated revascularization. The most common stent associated complication is thrombosis, which leads to mortality and morbidity. Antiplatelet therapy is required in routine basis to prevent stent thrombosis after PCI with baremetal stents.

According to studies and analysis, nearly 5% of patients with coronary stents need noncardiac surgery (NCS) within one year of PCI. Intravascular stent infection is another risk associated with PCI surgery with bare-metal stent. In few cases, this type of infection can be prevented with the use of prophylactic antibiotics at stent placement. Hence, few post-operative risks related to bare-metal stents is projected to restrain the market.

Request a Custom Report on “Bare-metal Stents Market” here @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=72336

Global Bare-metal Stents Market – Competitive Landscape

Major players operating in the global bare-metal stents market include Boston Scientific Corporation, Medtronic, B. Braun Melsungen AG, Biosensors International Group, Ltd, Hexacath,

Meril Life Sciences Pvt. Ltd., Genoss Co., Ltd., ELLA-CS, s.r.o., eucatech AG, Andramed, and pfm medical ag.

Boston Scientific Corporation

Boston Scientific Corporation offers innovative medical devices for improving the health of patients across the world. The company has operations in over 40 countries, with commercial representation in more than 130 countries. It generates more than 55% sales from the U.S. alone.

Boston Scientific Corporation operates through three business segments: medsurg, rhythm & neuro, and cardiovascular. The company’s REBEL platinum chromium stent system is a bare-metal stent used in coronary intervention. In 2018, the company announced agreement to acquire BTG plc, a leader in minimally invasive therapies, to enhance its portfolio in cancer and vascular diseases.

Medtronic

Founded in 1949 and headquartered in Dublin, Ireland, Medtronic is the world’s leading medical technology and solution company. It generates majority of its sales and revenue from the U.S. Reportable business segments include cardiac & vascular group, minimally invasive therapies group, restorative therapies group, and diabetes group. Medtronic provides services to hospitals, clinicians, physicians, and patients in more than 150 countries. In July 2019, Medtronic entered into a partnership agreement with Viz.ai, an emerging company in applied intelligence in stroke care.

...